Telomir Pharma - נכסים נקיים למניה בודדת TELO

Risks for Telomir Pharmaceuticals (TELO) are linked to its dependence on the success of clinical trials and the patent protection of small molecules. The book value per share visualizes these fluctuations, where 0.07 determines the current status of the parameter. Stability is provided by its status as an innovator in cellular rejuvenation and its independence from macroeconomic cycles, which makes the company's assets recession-resistant.

To minimize investment risks, it is essential to assess the actual net asset value, particularly in capital-intensive projects focused on creating a longevity ecosystem and developing telomeric drugs for Telomir Pharmaceuticals (TELO). The current book value trend reflects the remaining equity after all debts are settled, allowing the investor to see the true material foundation of the business beyond market speculation.